首页> 外文期刊>生物医学与环境科学(英文版) >Structural Modulation of Gut Microbiota in Rats with Allergic Bronchial Asthma Treated with Recuperating Lung Decoction
【24h】

Structural Modulation of Gut Microbiota in Rats with Allergic Bronchial Asthma Treated with Recuperating Lung Decoction

机译:调理肺汤对过敏性支气管哮喘大鼠肠道菌群的结构调控

获取原文
获取原文并翻译 | 示例
       

摘要

ObjectiveTo investigate whether recuperating lung decoction (RLD) can modulate the composition of gut microbiota in rats during asthma treatment. MethodsFifteen Sprague-Dawley rats were divided randomly and equally into control group, model group, dexamethasone (DEX) group, RLD medium-dose group, and RLD high-dose group. The asthma model was established in all groups, except for the control group. The rats in the DEX and RLD groups were treated orally with DEX and RLD, respectively. The rats in the control and model groups were treated orally with 0.9% saline. The intestinal bacterial communities were compared among groups using 16S rRNA gene amplification and 454 pyrosequencing. ResultsThe microbial flora differed between the control and model groups, but the flora in the RLD groups was similar to that in the control group. No significant differences were observed between the RLD high-dose and medium-dose groups. RLD treatment resulted in an increase in the level beneficial bacteria in the gut, such asLactobacillusandBifidobacteriumspp. ConclusionOral administration of RLD increased the number of intestinal lactic acid-producing bacteria, such as Lactobacillus andBifidobacterium, in asthma model rats.
机译:ObjectiveTo调查哮喘治疗期间患有肺汤(RLD)是否可以调节大鼠肠道微生物的组成。方法将Frague-Dawley大鼠随机,同等地分为对照组,模型组,地塞米松(DEX)组,RLD中剂量组和RLD高剂量组。除对照组外,所有群体建立了哮喘模型。 DEX和RLD基团的大鼠分别用DEX和RLD治疗。对照和模型组中的大鼠以0.9%的盐水口服处理。使用16S rRNA基因扩增和454个焦肉测序比较肠细菌群落。结果菌群与模型组之间的微生物菌群不同,但RLD基团中的植物群类似于对照组。在RLD高剂量和中剂量基团之间没有观察到显着差异。 RLD治疗导致肠道水平有益细菌增加,如洛替氏菌毒蕈唑杆菌细菌纤维杆菌。结论哮喘模型大鼠在哮喘模型大鼠中,RLD施用RLD的数量增加肠乳酸产生细菌的数量,例如乳酸杆菌和白杆菌。

著录项

  • 来源
    《生物医学与环境科学(英文版)》 |2016年第8期|574-583|共10页
  • 作者单位

    Beijing University of Chinese Medicine, Beijing 100029, China;

    Second Department of TCM Pulmonary Disease, The Key Institute of State Administration of Traditional Chinese Medicine pneumonopathy chronic cough and dyspnea, Beijing Key LaboratoryN0. BZ0321, China-Japan Friendship Hospital, Beijing 100029, China;

    State Key Laboratory for Infectious Diseases Prevention and Control, and National Institute for Communicable Disease Control and Prevention, Beijing 102206, China, Chinese Center forDisease Control and Prevention. Collaborative Innovation Center Diagnosis and Treatment of Infectious Disease,Hangzhou 310003, Zhejiang, China;

    Beijing University of Chinese Medicine, Beijing 100029, China;

    Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, China;

    Nephrology Department, Aviation General Hospital of China Medical University, Beijing 100012, China;

    Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, China;

    Second Department of TCM Pulmonary Disease, The Key Institute of State Administration of Traditional Chinese Medicine pneumonopathy chronic cough and dyspnea, Beijing Key LaboratoryN0. BZ0321, China-Japan Friendship Hospital, Beijing 100029, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号